Specifically activated memory T cell subsets from cancer patients recognize and reject xenotransplanted autologous tumors.
about
Effector, Memory, and Dysfunctional CD8(+) T Cell Fates in the Antitumor Immune ResponseCellular Immune Responses and Immune Escape Mechanisms in Breast Cancer: Determinants of ImmunotherapyBone Marrow T Cells and the Integrated Functions of Recirculating and Tissue-Resident Memory T CellsTumor specific regulatory T cells in the bone marrow of breast cancer patients selectively upregulate the emigration receptor S1P1.Tumor vaccine composed of C-class CpG oligodeoxynucleotides and irradiated tumor cells induces long-term antitumor immunity.Randomized controlled phase I/II study to investigate immune stimulatory effects by low dose radiotherapy in primarily operable pancreatic cancerPrinciples of adoptive T cell cancer therapy.A randomized controlled trial to investigate the influence of low dose radiotherapy on immune stimulatory effects in liver metastases of colorectal cancer.Intratumoral Immune Responses Can Distinguish New Primary and True Recurrence Types of Ipsilateral Breast Tumor Recurrences (IBTR)Tumor-specific cytotoxic T lymphocyte activity determines colorectal cancer patient prognosis.Anti-angiogenic activity of VXM01, an oral T-cell vaccine against VEGF receptor 2, in patients with advanced pancreatic cancer: A randomized, placebo-controlled, phase 1 trial.A randomized phase II study of radiation induced immune boost in operable non-small cell lung cancer (RadImmune trial).Significance of heparanase in cancer and inflammation.Immunisation with 'naïve' syngeneic dendritic cells protects mice from tumour challenge.HLA-A2-restricted cytotoxic T lymphocyte epitopes from human heparanase as novel targets for broad-spectrum tumor immunotherapy.CD4+ T effector memory cell dysfunction is associated with the accumulation of granulocytic myeloid-derived suppressor cells in glioblastoma patients.Tumor immunoediting and immunosculpting pathways to cancer progression.High avidity myeloid leukemia-associated antigen-specific CD8+ T cells preferentially reside in the bone marrow.In vivo functional efficacy of tumor-specific T cells expanded using HLA-Ig based artificial antigen presenting cells (aAPC).Antigen-specific Tregs control T cell responses against a limited repertoire of tumor antigens in patients with colorectal carcinoma.Targeting the autophagy pathway for cancer chemoprevention.Adoptively transferred human lung tumor specific cytotoxic T cells can control autologous tumor growth and shape tumor phenotype in a SCID mouse xenograft model.Impact of the Tumor Microenvironment on Tumor-Infiltrating Lymphocytes: Focus on Breast Cancer.Clinical responses to adoptive T-cell transfer can be modeled in an autologous immune-humanized mouse model.Development of immune memory to glial brain tumors after tumor regression induced by immunotherapeutic Toll-like receptor 7/8 activation.FOXOs in Cancer Immunity: Knowns and Unknowns.Functional T cells targeting tumor-associated antigens are predictive for recurrence-free survival of patients with radically operated non-small cell lung cancer.Immune Response against ALK in Children with ALK-Positive Anaplastic Large Cell Lymphoma.
P2860
Q26744527-81326EDA-64FF-498F-BFBA-F83A862DE167Q26745444-0E7E8BD7-ED30-4F6A-AD53-7516B7D0FBC1Q26766714-CB0BAB0B-A632-4F57-8BE4-75FDCDEBED7DQ33607086-7F4E81C6-7104-45BC-889F-B341A49C0069Q33690978-9B14CD80-AEA6-4C5B-B7EC-3B2D1F8123CBQ33871724-D4E11085-84D8-49B0-8141-762A422AFD2DQ34003932-CA4938D5-F2A4-4233-9C51-24F2FBF6F712Q34036020-29AC1294-676A-470A-B781-29F6F5CC295FQ35052534-81ABD4FB-0DA6-4351-80B0-D8AE7DC403BBQ35056748-AEDD9FC6-9897-4C9D-A510-693E3DBEA710Q35798947-A25B0B24-0B16-4C24-BBCB-0A0146FF4468Q35873571-141D0552-613F-4589-B9C1-741EA16F5AD6Q36101233-BB381CCF-F5BC-49A3-8AB6-1A1022CC8926Q36484597-D4514B21-2D84-41E0-B5D8-B624BFA63EACQ36840281-57825711-13C9-4E5F-A353-9DFEF3DF3477Q36893225-56AA6ACA-61E4-493B-A0BC-9CFF5E45E201Q36896195-0AD89316-28DE-4A0B-BD2F-932B2FBE2F93Q37119914-F6B7B6AB-6DC2-47A2-9779-EB02E3EC0F10Q37186903-D0FD8C76-AFE0-49F7-B48B-38AFCDC38EA7Q37403114-9EE109B0-6A2A-4E70-9D82-C1F907498CC5Q38469581-52892707-BD02-4BCC-ACED-A1CF852F621DQ40115182-6DE51D6D-6B6D-4542-B30D-C6A48A01EE8BQ41810793-38E94A80-5993-40D2-A856-A9E0B23BC028Q41915301-678DD5DD-0566-43BF-B8C4-29A640E23BACQ41979125-65A19329-44AC-43EB-AE1E-73D76017F3EEQ47224295-C32F65F6-1E3D-47A3-80BE-35557F6E75C8Q47581436-6A62B6E9-D2C3-4B74-A646-F35CB2552CC4Q54981113-DF5E8C8C-2DE3-4A99-9D7F-05D362844936
P2860
Specifically activated memory T cell subsets from cancer patients recognize and reject xenotransplanted autologous tumors.
description
2004 nî lūn-bûn
@nan
2004 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Specifically activated memory ...... ransplanted autologous tumors.
@ast
Specifically activated memory ...... ransplanted autologous tumors.
@en
type
label
Specifically activated memory ...... ransplanted autologous tumors.
@ast
Specifically activated memory ...... ransplanted autologous tumors.
@en
prefLabel
Specifically activated memory ...... ransplanted autologous tumors.
@ast
Specifically activated memory ...... ransplanted autologous tumors.
@en
P2093
P2860
P356
P1476
Specifically activated memory ...... ransplanted autologous tumors.
@en
P2093
Carmen Choi
Florian Schuetz
Gunther Bastert
Jochen Schwendemann
Katrin Ehlert
Markus Feuerer
Mathias Dolenc
Nora Sommerfeldt
Peter Altevogt
Philipp Beckhove
P2860
P356
10.1172/JCI20278
P407
P577
2004-07-01T00:00:00Z